Eli Lilly and Company

- The transcript does not mention any current or planned fundraising activities through debt or equity. - It highlights strong operational momentum with robust revenue growth, increased earnings, and business development via acquisitions. - The company paid $1.5 billion in dividends and repurchased $2.4 billion in shares during the quarter, indicating confidence in cash flow. - There is no direct reference to issuing new debt or equity to raise funds. - Investments appear funded through existing resources, focusing on pipeline development, acquisitions, and ongoing operational expenses. - Management emphasizes investing in future medicines and expanding pipeline through organic growth and acquisitions rather than external fundraising at this time.

- Eli Lilly is actively investing in future medicines, with a focus on a record number of ongoing Phase III trials (42 programs). - The company emphasizes capital deployment across a very full Phase II and Phase I pipeline. - Recent strategic investments include acquisitions of Orna Therapeutics, Centessa Pharmaceuticals, Ventix Biosciences, Colonia Therapeutics, and Ajax Therapeutics, expanding capabilities in immunology, oncology, neuroscience, inflammation, and gene therapies. - Lilly is investing in next-generation obesity medicines such as retatrutide and oloralintide, with multiple Phase III programs underway. - Marketing, selling, and administrative expenses increased by 19%, and R&D costs grew by 28%, indicating strong investment in commercialization and innovation. - The company has flexibility in margin and cost structures to support these investments despite pricing pressures. - Strategic collaborations and licensing agreements (e.g., CSL for clasikizumab) also form part of investment activities.

- Eli Lilly raised 2026 revenue guidance by $2 billion at both ends, now projecting $82 billion to $85 billion. - Non-GAAP EPS guidance increased to $3.25 to $3.50 per share, reflecting strong portfolio performance. - Foundayo (oral GLP-1) early launch shows promising uptake with over 20,000 patients treated, expected to accelerate as prescriber familiarity grows. - International Mounjaro launch strong across 55+ countries, with >60% market share in key markets, expected to sustain robust year-on-year and sequential growth. - Medicare Part D access for obesity medicines begins July 2026, projected to ramp through 2027 as patient activation and affordability improve. - Pricing strategies drive nonlinear volume expansion, particularly in out-of-pocket markets. - Continued investment in pipeline and marketing aims to support growth across obesity, diabetes, immunology, oncology, and neuroscience segments. - Digital, social, and DTC campaigns planned to further accelerate Foundayo's market penetration in Q3 2026 onward.

- 2026 revenue guidance raised by $2 billion on both ends, now expected between $82 billion and $85 billion. - Midpoint of the revenue range represents 28% growth compared to 2025. - Non-GAAP performance margin projected between 47% and 48.5%, driven by higher revenue. - Non-GAAP earnings per share (EPS) guidance increased to a range of $3.00 to $3.52. - Early Foundayo sales tracking to internal expectations but not yet a principal factor in guidance increase. - Continued investments in pipeline and promotional activities expected, with 42 active Phase III programs. - Management confident in delivering another year of industry-leading growth supported by strength across the portfolio including Mounjaro, Zepbound, and Foundayo.

- Over 20,000 patients have been treated with Foundayo (orforglipron) to date. - 80% of these Foundayo prescriptions are new to the GLP-1 class, indicating expanding market penetration. - More than 8,000 prescribers have written Foundayo prescriptions so far. - Execution is ongoing with sampling and seminars to support field engagement. - Commercial access for Foundayo has been confirmed at two large PBMs by mid-May. - Medicare Part D access for Foundayo will begin in July 2026 and continue through 2027. - Early launch indicators for Foundayo are tracking well with expectations, though it is still early with only a few weeks of data. - Ongoing efforts include digital, social, DTC, and upcoming TV campaigns planned for Q3 2026 once prescriber familiarity increases.